- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/64 - One oxygen atom attached in position 2 or 6
Patent holdings for IPC class C07D 213/64
Total number of patents in this class: 964
10-year publication summary
|
74
|
78
|
58
|
67
|
65
|
51
|
56
|
55
|
48
|
33
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Epizyme, Inc. | 360 |
27 |
| Abbvie Inc. | 1824 |
17 |
| Bristol-myers Squibb Company | 4751 |
15 |
| Boehringer Ingelheim International GmbH | 4493 |
14 |
| F. Hoffmann-La Roche AG | 7819 |
12 |
| Inflazome Limited | 84 |
12 |
| Bayer Pharma AG | 1009 |
11 |
| Eli Lilly and Company | 4106 |
11 |
| Mitsui Chemicals Agro, Inc. | 79 |
10 |
| Takeda Pharmaceutical Company Limited | 2710 |
10 |
| Nippon Soda Co., Ltd. | 882 |
10 |
| Calico Life Sciences LLC | 111 |
9 |
| Pfizer Inc. | 3396 |
8 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
8 |
| Centre National de La Recherche Scientifique | 11026 |
7 |
| Celgene Quanticel Research, Inc. | 154 |
7 |
| Gilead Sciences, Inc. | 2226 |
7 |
| Merck Sharp & Dohme LLC | 3736 |
7 |
| Hoffmann-La Roche Inc. | 3796 |
6 |
| Genentech, Inc. | 4110 |
6 |
| Other owners | 750 |